Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12963494 | 0.86 | RAPGEF4 (0.50) | RAPGEF4ALDH1A1LMNAMAPTCRHR1 | |
| SCHEMBL12909372 | 0.84 | RAPGEF4 (0.44) | RAPGEF4ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL22118789 | 0.76 | MAPK14 (0.39) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL19437477 | 0.74 | KDM4E (0.43) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL2756366 | 0.74 | RAPGEF4 (0.57) | RAPGEF4ALDH1A1LMNAMAPTGAA | |
| SCHEMBL21015410 | 0.74 | MAPT (0.56) | RAPGEF4ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL19908710 | 0.73 | CNR2 (0.36) | RAPGEF4ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL3635788 | 0.73 | CD44 (0.43) | ALDH1A1LMNAMAPTKDM4EGAA | |
| SCHEMBL23009590 | 0.73 | RAPGEF4 (0.50) | RAPGEF4ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL13917945 | 0.71 | RAPGEF4 (0.48) | RAPGEF4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | RAPGEF4 4560/4885ALDH1A1 45/4885LMNA 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.